SeaCrest Wealth Management LLC Sells 22,522 Shares of Bristol-Myers Squibb (NYSE:BMY)

SeaCrest Wealth Management LLC trimmed its position in Bristol-Myers Squibb (NYSE:BMY) by 58.7% during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 15,817 shares of the biopharmaceutical company’s stock after selling 22,522 shares during the quarter. SeaCrest Wealth Management LLC’s holdings in Bristol-Myers Squibb were worth $858,000 at the end of the most recent reporting period.

Several other large investors have also recently made changes to their positions in the company. Naviter Wealth LLC increased its holdings in shares of Bristol-Myers Squibb by 64.3% in the first quarter. Naviter Wealth LLC now owns 23,719 shares of the biopharmaceutical company’s stock worth $1,286,000 after purchasing an additional 9,284 shares during the last quarter. Quattro Financial Advisors LLC increased its holdings in shares of Bristol-Myers Squibb by 88,135.3% in the first quarter. Quattro Financial Advisors LLC now owns 45,000 shares of the biopharmaceutical company’s stock worth $2,440,000 after purchasing an additional 44,949 shares during the last quarter. State of Michigan Retirement System increased its holdings in shares of Bristol-Myers Squibb by 208.3% in the first quarter. State of Michigan Retirement System now owns 1,924,733 shares of the biopharmaceutical company’s stock worth $104,378,000 after purchasing an additional 1,300,400 shares during the last quarter. Westhampton Capital LLC increased its holdings in shares of Bristol-Myers Squibb by 63.2% in the first quarter. Westhampton Capital LLC now owns 9,667 shares of the biopharmaceutical company’s stock worth $541,000 after purchasing an additional 3,745 shares during the last quarter. Finally, AlphaMark Advisors LLC increased its holdings in shares of Bristol-Myers Squibb by 2.3% in the first quarter. AlphaMark Advisors LLC now owns 22,605 shares of the biopharmaceutical company’s stock worth $1,226,000 after purchasing an additional 514 shares during the last quarter. 76.41% of the stock is owned by institutional investors.

Analyst Ratings Changes

Several research analysts recently commented on the company. William Blair reiterated a “market perform” rating on shares of Bristol-Myers Squibb in a research report on Monday, April 1st. Barclays dropped their price target on Bristol-Myers Squibb from $51.00 to $43.00 and set an “equal weight” rating for the company in a research report on Friday, April 26th. BMO Capital Markets dropped their price target on Bristol-Myers Squibb from $55.00 to $48.00 and set a “market perform” rating for the company in a research report on Friday, April 26th. Wells Fargo & Company lifted their price target on Bristol-Myers Squibb from $51.00 to $52.00 and gave the stock an “equal weight” rating in a research report on Thursday, April 18th. Finally, StockNews.com lowered Bristol-Myers Squibb from a “strong-buy” rating to a “buy” rating in a research report on Thursday, June 27th. One investment analyst has rated the stock with a sell rating, fifteen have given a hold rating and four have assigned a buy rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus price target of $60.00.

Bristol-Myers Squibb Stock Performance

Shares of NYSE:BMY opened at $40.06 on Thursday. The company has a market capitalization of $81.21 billion, a price-to-earnings ratio of -12.92, a price-to-earnings-growth ratio of 14.21 and a beta of 0.44. Bristol-Myers Squibb has a 52 week low of $39.63 and a 52 week high of $65.38. The company has a quick ratio of 0.99, a current ratio of 1.11 and a debt-to-equity ratio of 2.99. The firm has a 50 day moving average of $42.64 and a 200 day moving average of $47.97.

Bristol-Myers Squibb (NYSE:BMY) last issued its quarterly earnings data on Thursday, April 25th. The biopharmaceutical company reported ($4.40) EPS for the quarter, topping analysts’ consensus estimates of ($4.53) by $0.13. The company had revenue of $11.87 billion during the quarter, compared to the consensus estimate of $11.45 billion. Bristol-Myers Squibb had a negative net margin of 13.50% and a positive return on equity of 8.83%. Bristol-Myers Squibb’s revenue for the quarter was up 4.7% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $2.05 earnings per share. On average, sell-side analysts predict that Bristol-Myers Squibb will post 0.58 earnings per share for the current fiscal year.

Bristol-Myers Squibb Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, August 1st. Investors of record on Friday, July 5th will be paid a $0.60 dividend. This represents a $2.40 dividend on an annualized basis and a yield of 5.99%. The ex-dividend date of this dividend is Friday, July 5th. Bristol-Myers Squibb’s dividend payout ratio (DPR) is -77.42%.

About Bristol-Myers Squibb

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.